PMA device
VisuMax
Carl Zeiss Meditec, Inc. · Femtosecond Laser System For Refractive Correction (OTL, Class III) · First FDA decision Sep 13, 2016, newest Dec 18, 2025Nearsightedness and refractive error
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
6
PMA pathway
Device trials
15
Naming "VisuMax"
MAUDE reports
66
Brand "VisuMax", since 2015
PubMed studies
282
Mentioning "VisuMax"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing VisuMax
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 6 of 6 decisions filed under this name.
- VisuMax; VISUMAX 800PMA supplement
P150040-S020 · Decided Dec 18, 2025 · 178 days after receipt · Normal 180 Day Track No User Fee
Device type: Femtosecond laser system for refractive correction (OTL) · Ophthalmology
- VisuMax Femtosecond LaserPMA supplement
P150040-S013 · Decided Apr 13, 2023 · 30 days after receipt · Normal 180 Day Track No User Fee
Device type: Femtosecond laser system for refractive correction (OTL) · Ophthalmology
- VisuMax Femtosecond LaserPMA supplement
P150040-S008 · Decided Feb 19, 2021 · 92 days after receipt · Normal 180 Day Track
Device type: Femtosecond laser system for refractive correction (OTL) · Ophthalmology
3 more FDA decisions with a free account
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "VisuMax", any status and sponsor, newest update first.
- Fresh Corneal Lenticule Implantation in Hyperopic Patients With High AstigmatismActive, not recruiting
Eye Hospital Pristina KosovoAcademic, hospital or other
NCT04616144 · 55 participants (planned) · Start May 1, 2019 · Primary completion May 1, 2020
Device: Fresh Corneal Lenticule Implantation using Relex-Smile VisuMax Femtosecond Laser · For: Hyperopia; High Astigmatism
Sites: Pristina, Kosovo
- Human Fresh Corneal Lenticule Implantation Criteria in Progressive Corneal Disease Using Relex-SmileEnrolling by invitation
Eye Hospital Pristina KosovoAcademic, hospital or other
NCT04848740 · 100 participants (planned) · Start Feb 1, 2018 · Primary completion Feb 1, 2027
Device: ReLex-smile · For: Progressive Disease of Corneae
Sites: Pristina, Kosovo
Carl Zeiss Meditec, Inc.Not on our public-company list
NCT01638390 · 357 participants · Start Jul 2012 · Primary completion Apr 2016
Device: Treatment with the VisuMax™ Femtosecond Laser · For: Myopia
Sites: Greenwood Village, Colorado; Miami, Florida; Leawood, Kansas · 5 sites in all
12 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "VisuMax", and for the whole product code for context.
This brand
66 reports: 6 malfunction, 60 injury, 0 death
Whole product code OTL
74 reports: 5 malfunction, 69 injury, 0 death
Newest reports for this brand
- VISUMAX 800Injury
9615030-2026-00022 · Received Jul 15, 2026 · Event dated Apr 15, 2026
Device type: Femtosecond Laser System For Refractive Correction (OTL)
Device problem as coded: Use of Device Problem; Operating System Version or Upgrade Problem
Patient problem as coded: Visual Impairment
9615030-2026-00019 · Received Jun 5, 2026 · Event dated Jun 1, 2023
Device type: Femtosecond Laser System For Refractive Correction (OTL)
Device problem as coded: Patient-Device Incompatibility; Insufficient Device Problem Information; Patient Device Interaction Problem
Patient problem as coded: Dry Eye(s); Visual Impairment; Visual Disturbances; Halo; Anxiety; Distress; Discomfort; Corneal Thinning
- VISUMAXInjury
9615030-2026-00018 · Received May 21, 2026 · Event dated Feb 7, 2025
Device type: Femtosecond Laser System For Refractive Correction (OTL)
Device problem as coded: Adverse Event Without Identified Device or Use Problem
Patient problem as coded: Visual Impairment
2 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
Z-0680-2020 · Started Dec 6, 2018
Reason given: VisuMax devices with software version 2.10.13 and activated SW-Module ReLEx (SMILE) option may experience a software issue. In case of a suction loss during treatment the software allows the user to choose the option immediate restart or restart treatment. Suction loss can occur in phase 1 through phase 5. The...
Cause as FDA categorized it: Software design · Device type: Femtosecond Laser System For Refractive Correction (OTL)
Published research
The most relevant PubMed records for "VisuMax"[tiab]. The summary above synthesizes these.
- Lamellar surgeries with SMILE-derived lenticules.
Ganesh S, Brar S, Chopra R · Taiwan J Ophthalmol · 2024
- Femtosecond laser deep lamellar keratoplasty.
Farid M, Rostov AT · Indian J Ophthalmol · 2022
- Comparison of Visual and Refractive Outcomes of Keratorefractive Lenticule Extraction for Compound Myopic Astigmatism Between VisuMax and VISUMAX 800.
Varman A, Varman A, Balakumar D · Clin Ophthalmol · 2024
- Visumax femtolasik versus Moria M2 microkeratome in mild to moderate myopia: efficacy, safety, predictability, aberrometric changes and flap thickness predictability.
Torky MA, Al Zafiri YA, Khattab AM, et al. · BMC Ophthalmol · 2017
- Refractive outcomes of small lenticule extraction (SMILE) Pro® with a 2 MHz femtosecond laser.
Saad A, Klabe K, Kirca M, et al. · Int Ophthalmol · 2024
- VisuMax Flap 2.0: a flap plus technique to reduce incidence of an opaque bubble layer in femtosecond laser-assisted LASIK.
Wang Z, Cheng X, Lou X, et al. · Graefes Arch Clin Exp Ophthalmol · 2023
- Advances in refractive corneal lenticule extraction.
Fuest M, Mehta JS · Taiwan J Ophthalmol · 2021Review
- CIRCLE Enhancement After Myopic SMILE.
Siedlecki J, Luft N, Mayer WJ, et al. · J Refract Surg · 2018
- Refractive and Visual Outcomes of SMILE for Compound Myopic Astigmatism With the VISUMAX 800.
Reinstein DZ, Archer TJ, Potter JG, et al. · J Refract Surg · 2023
- Comparison of clinical outcomes following small incision lenticule extraction performed with the visumax 800 versus visumax 500 femtosecond laser.
Kim BK, Chung YT · Sci Rep · 2025Comparative Study
- [Femtosecond laser-assisted keratoplasty].
Módis L, Szalai E, Flaskó Z, et al. · Orv Hetil · 2018
- Corneal stromal roughness after VisuMax and Intralase femtosecond laser photodisruption: An atomic force microscopy study.
Gros-Otero J, Ketabi S, Cañones-Zafra R, et al. · PLoS One · 2021Research Support, Non-U.S. Gov't
Other devices of this type
Also filed under product code OTL.
- Visumax 800Carl Zeiss Meditec, Inc. · PMA 2024
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.